Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC36745 Nintedanib esylate

    Nintedanib esylate, as a kinase inhibitor, used for the treatment of non-small cell lung cancer suffered from first-pass metabolism which resulted in low oral bioavailability .

     Nintedanib esylate Chemical Structure
  3. GN10325 Nobiletin Nobiletin Chemical Structure
  4. GC14075 Nocodazole A tubulin production inhibitor,anti-neoplastic agent Nocodazole Chemical Structure
  5. GC50152 Norleual

    Highly potent HGF/c-MET inhibitor; also AT4 antagonist

     Norleual Chemical Structure
  6. GC69584 Norleual TFA

    Norleual TFA is a type IV angiotensin (Ang) similar substance and a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM. It is also an AT4 antagonist with strong anti-angiogenic activity.

     Norleual TFA Chemical Structure
  7. GC14488 NPS-1034 MET inhibitor NPS-1034 Chemical Structure
  8. GC33131 NRC-2694 NRC-2694 is an epidermal growth factor receptor (EGFR) antagonist with anti-cancer and anti-proliferative properties. NRC-2694 Chemical Structure
  9. GC14103 NSC228155 EGFR activator NSC228155 Chemical Structure
  10. GC69596 NSC689857

    NSC689857 is an effective inhibitor of EGFR and SCFSKP2, with an IC50 of 36 μM against Skp2-Cks1. NSC689857 can inhibit phosphorylation of p27 (IC50=30 μM). NSC689857 exhibits varying activity in different types of cancer, with higher resistance activity against leukemia cell lines compared to other cancer cells.

     NSC689857 Chemical Structure
  11. GC12712 NT157 IRS-1/2 inhibitor, inhibits IGF-1R and STAT3 signaling pathway NT157 Chemical Structure
  12. GC69599 NT219

    NT219 is an effective dual inhibitor of insulin receptor substrate 1/2 (IRS1/2) and STAT3. IRS1/2 and STAT3 are major signaling pathways regulated by various oncogenes. NT219 affects the degradation of IRS1/2 and inhibits the phosphorylation of STAT3. NT219 has potential for researching cancer diseases.

     NT219 Chemical Structure
  13. GC10720 NTR 368 cytoplasmic peptide of the neurotrophin receptor p75NTR NTR 368 Chemical Structure
  14. GC34126 NVP-ACC789 (ACC-789) NVP-ACC789 (ACC-789) is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively. NVP-ACC789 (ACC-789) Chemical Structure
  15. GC14310 NVP-ADW742 Selective IGF-1R inhibitor NVP-ADW742 Chemical Structure
  16. GC12963 NVP-AEW541 IGF-IR inhibitor, novel, potent and selective NVP-AEW541 Chemical Structure
  17. GC16028 NVP-BGJ398 phosphate NVP-BGJ398 phosphate Chemical Structure
  18. GC14332 NVP-BHG712 EphB4 inhibitor,potent and selective NVP-BHG712 Chemical Structure
  19. GC36782 NVP-BHG712 isomer NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4. NVP-BHG712 isomer Chemical Structure
  20. GC16972 NVP-BVU972 C-Met inhibitor,potent and selective NVP-BVU972 Chemical Structure
  21. GC44491 O-Desmethyl Gefitinib O-Desmethyl gefitinib is the major metabolite of gefitinib in human plasma, formed by the cytochrome P450 isoform CYP2D6. O-Desmethyl Gefitinib Chemical Structure
  22. GC68321 O-Desmethyl gefitinib-d8 O-Desmethyl gefitinib-d8 Chemical Structure
  23. GC64950 ODM-203 ODM-203 is an orally active and selective FGFR/VEGFR inhibitor with IC50 values of 6, 11, 16, 5, 9, 26 and 35 nM for FGFR3/1/2 and VEGFR3/2/1/4, respectively. ODM-203 has strong anti-tumour activity and activates immune responses in the tumour microenvironment. ODM-203 Chemical Structure
  24. GC32502 Oglufanide (H-Glu-Trp-OH) Oglufanide (H-Glu-Trp-OH) (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide (H-Glu-Trp-OH) Chemical Structure
  25. GC69619 Olaratumab

    Olaratumab (IMC-3G3; LY3012207) is a human monoclonal IgG1 antibody that targets platelet-derived growth factor receptor alpha (PDGFRα) and has anti-tumor activity.

     Olaratumab Chemical Structure
  26. GC15370 Olmutinib (HM61713, BI 1482694) Olmutinib (HM61713, BI 1482694) (HM61713; BI-1482694) is an orally active and irreversible third EGFR tyrosine kinase inhibitor that binds to a cysteine residue near the kinase domain. Olmutinib (HM61713, BI 1482694) is used for NSCLC. Olmutinib (HM61713, BI 1482694) Chemical Structure
  27. GC62207 Olverembatinib Olverembatinib (GZD824) is a potent and orally active pan-Bcr-Abl inhibitor. Olverembatinib potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib strongly inhibits native Bcr-Abl and Bcr-AblT315I with IC50s of 0.34 nM and 0.68 nM, respectively. Olverembatinib has antitumor activity. Olverembatinib Chemical Structure
  28. GC36807 ON 146040 ON 146040 is a potent PI3Kα and PI3Kδ (IC50≈14 and 20 nM, respectively) inhibitor. ON 146040 also inhibits Abl1 (IC50<150 nM). ON 146040 Chemical Structure
  29. GC69623 Onartuzumab

    Onartuzumab (MetMAb) is a humanized, affinity-matured monoclonal antibody that inhibits the receptor tyrosine kinase MET. Onartuzumab effectively inhibits HGF binding, receptor phosphorylation and signal transduction. Onartuzumab has antibody-like pharmacokinetics and anti-tumor activity.

     Onartuzumab Chemical Structure
  30. GC64770 Oritinib Oritinib (SH-1028), an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. Oritinib (SH-1028), a mutant-selective inhibitor of EGFR kinase activity, inhibits EGFRWT, EGFRL858R, EGFRL861Q, EGFRL858R/T790M, EGFRd746-750 and EGFRd746-750/T790M kinases, with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM, respectively. Oritinib Chemical Structure
  31. GC17530 OSI-420 OSI-420 (OSI-420) is an active metabolite of Erlotinib. Erlotinib is a potent EGFR tyrosin kinase inhibitor. OSI-420 Chemical Structure
  32. GC14957 OSI-930 Inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck OSI-930 Chemical Structure
  33. GC61161 Osimertinib D6 Osimertinib D6 Chemical Structure
  34. GC36819 Osimertinib dimesylate Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively. Osimertinib dimesylate Chemical Structure
  35. GA23328 Osteogenic Growth Peptide (10-14) YGFGG, C-terminal pentapeptide fragment of the osteogenic growth peptide (OGP), (H-8640), showed the full spectrum of OGP-like bioactivities. It has attracted considerable interest as bone anabolic agent and hematopoietic stimulator. Osteogenic Growth Peptide (10-14) Chemical Structure
  36. GC68433 OTS447 OTS447 Chemical Structure
  37. GC41329 Pacritinib FMS-like tyrosine kinase 3 (FLT3) and Janus kinase 2 (JAK2) are tyrosine kinases that mediate cytokine signaling and are frequently mutated in cancers, particularly acute myeloid leukemia. Pacritinib Chemical Structure
  38. GC66405 Panitumumab Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer. Panitumumab Chemical Structure
  39. GC66333 Panitumumab (anti-EGFR) Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer. Panitumumab (anti-EGFR) Chemical Structure
  40. GC69662 Parsatuzumab

    Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody that binds to EGFL7 as an immune modulator. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, which may inhibit angiogenesis and reduce the inhibition of vascular endothelial growth factor (VEGF).

     Parsatuzumab Chemical Structure
  41. GC69665 Patritumab

    Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody targeting ERBB3. Patritumab has synergistic effects with Cetuximab and can effectively inhibit the phosphorylation of EGFR, HER2, HER3, ERK and AKT. Patritumab also induces apoptosis and inhibits the growth of pancreatic, non-small cell lung cancer and colorectal cancer xenograft tumors.

     Patritumab Chemical Structure
  42. GC16327 Pazopanib (GW-786034) A multi-kinase inhibitor Pazopanib (GW-786034) Chemical Structure
  43. GC12730 Pazopanib Hydrochloride VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor Pazopanib Hydrochloride Chemical Structure
  44. GC40085 Pazopanib-d6 Pazopanib-d6 is intended for use as an internal standard for the quantification of pazopanib by GC- or LC-MS. Pazopanib-d6 Chemical Structure
  45. GC44583 PD 089828 PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 μM). PD 089828 Chemical Structure
  46. GC49617 PD 153035 A potent EGFR kinase inhibitor PD 153035 Chemical Structure
  47. GC15983 PD 153035 hydrochloride A highly potent EGFR inhibitor PD 153035 hydrochloride Chemical Structure
  48. GC15925 PD 158780 ErbB receptor family tyrosine kinase inhibitor PD 158780 Chemical Structure
  49. GC12049 PD 161570 FGFR inhibitor PD 161570 Chemical Structure
  50. GC15314 PD 166326 receptor tyrosine kinases inhibitor PD 166326 Chemical Structure
  51. GC17943 PD 173074 Inhibitor of tyrosine kinase activity of fibroblast growth factor receptors PD 173074 Chemical Structure
  52. GC44585 PD 174265 PD 174265 is a potent, cell-permeable inhibitor of the tyrosine kinase activity of the epidermal growth factor (EGF) receptor (IC50 = 0.45 nM). PD 174265 Chemical Structure
  53. GC12637 PD 180970 P210bcr/abl tyrosine kinase inhibitor PD 180970 Chemical Structure
  54. GC46197 PD 90780 (hydrate) An inhibitor of NGF-p75 NGFR interactions PD 90780 (hydrate) Chemical Structure
  55. GC19279 PD-166866 PD166866 is a selective FGFR1 tyrosine kinase inhibitor with an IC50 of 52.4 nM. PD-166866 Chemical Structure
  56. GC34105 PD153035 Hydrochloride (ZM 252868) A highly potent EGFR inhibitor PD153035 Hydrochloride (ZM 252868) Chemical Structure
  57. GC11015 PD168393 EGFR inhibitor PD168393 Chemical Structure
  58. GC13592 PD173955 Dual Src/Abl kinase inhibitor, ATP-competitive, PD173955 Chemical Structure
  59. GC65366 PDGFRα kinase inhibitor 1 PDGFRα kinase inhibitor 1 is a highly selective type II PDGFRα kinase inhibitor with IC50s of 132 nM and 6115 nM for PDGFRα and PDGFRβ, respectively. PDGFRα kinase inhibitor 1 Chemical Structure
  60. GC64346 Pegaptanib sodium Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib sodium Chemical Structure
  61. GC17473 Pelitinib (EKB-569) Pelitinib (EKB-569) (EKB-569;WAY-EKB 569) is an irreversible inhibitor of EGFR with an IC50 of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC50s of 282, 800, and 1255 nM, respectively. Pelitinib (EKB-569) Chemical Structure
  62. GC32915 Pemigatinib An FGFR inhibitor Pemigatinib Chemical Structure
  63. GC60283 Pentagamavunon-1 Pentagamavunon-1 (PGV-1), a Curcumin analog with oral activity, targets on several molecular mechanisms to induce apoptosis including inhibition of angiogenic factors cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF). PGV-1 inhibits NF-κB activation. Pentagamavunon-1 Chemical Structure
  64. GC47938 Pericosine A A fungal metabolite with anticancer activity Pericosine A Chemical Structure
  65. GC34210 Pertuzumab (Anti-Human HER2, Humanized Antibody) Pertuzumab (Anti-Human HER2, Humanized Antibody), the first of a new class of agents designated as HER dimerisation inhibitors, is a humanised IgG1 monoclonal antibody (mAb) that sterically binds domain II of the erbB2 receptor . Pertuzumab (Anti-Human HER2, Humanized Antibody) Chemical Structure
  66. GC69690 Petosemtamab

    Petosemtamab (MCLA 158) is a monoclonal antibody (mAb) that targets both EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab blocks EGFR signaling and receptor degradation in LGR5+ cancer cells. It can be used for research on solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc.

     Petosemtamab Chemical Structure
  67. GC44605 Petunidin (chloride)

    Petunidin is an O-methylated anthocyanidin derived from delphinidin that imparts blue-red pigments to flowers, fruits, and red wine.

     Petunidin (chloride) Chemical Structure
  68. GC12222 Pexidartinib (PLX3397) Pexidartinib (PLX3397) (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib (PLX3397) (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX3397) (PLX-3397) induces cell apoptosis and has anti-tumor activity. Pexidartinib (PLX3397) Chemical Structure
  69. GC34708 Pexidartinib hydrochloride Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity. Pexidartinib hydrochloride Chemical Structure
  70. GC50346 PF 06273340 Potent and selective pan-Trk inhibitor; peripherally restricted PF 06273340 Chemical Structure
  71. GC17630 PF 06465469 inhibitor of interleukin-2 inducible T cell kinase (ITK) and Bruton's tyrosine kinase (BTK) PF 06465469 Chemical Structure
  72. GC14767 PF-00562271 PF-562271 (VS-6062) besylate is a potent ATP-competitive, reversible inhibitor of FAK and Pyk2 kinase, with an IC50 of 1.5 nM and 13 nM, respectively. PF-00562271 Chemical Structure
  73. GC18074 PF-03814735 An inhibitor of Aurora A and B kinases PF-03814735 Chemical Structure
  74. GC12729 PF-04217903 C-Met inhibitor,selective and ATP-competitive PF-04217903 Chemical Structure
  75. GC15733 PF-04217903 methanesulfonate A c-Met inhibitor PF-04217903 methanesulfonate Chemical Structure
  76. GC31495 PF-05231023 PF-05231023 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. PF-05231023 Chemical Structure
  77. GC13850 PF-06447475 LRRK2 inhibitor PF-06447475 Chemical Structure
  78. GC64566 PF-06454589 PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC50 values of 3 nM and 11 nM for WT LRRK and G2019S LRRK2, respectively. PF-06454589 Chemical Structure
  79. GC64506 PF-06456384 trihydrochloride PF-06447475 trihydrochloride is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC50 values of 3 nM and 11 nM for WT LRRK and G2019S LRRK2, respectively. PF-06456384 trihydrochloride Chemical Structure
  80. GC32927 PF-06459988 PF-06459988 is an orally activity, irreversible and mutant-selective inhibitor of EGFR mutant forms. PF-06459988 demonstrates high potency and specificity to the T790M-containing double mutant EGFRs. PF-06459988 can be used for the research of cancer. PF-06459988 Chemical Structure
  81. GC14794 PF-06463922 PF-06463922 (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive ROS1/ALK inhibitor. PF-06463922 has Kis of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALKL1196M, respectively. PF-06463922 has anticancer activity. PF-06463922 Chemical Structure
  82. GC34710 PF-06747711 PF-06747711 is a potent, selective, and orally active retinoic acid receptor-related orphan C2 (RORC2, also known as RORγt) inverse agonist, with an IC50 of 4.1 nM. PF-06747711 Chemical Structure
  83. GC14407 PF-431396 Pyk2 and FAK inhibitor PF-431396 Chemical Structure
  84. GC61852 PF-4618433 PF-4618433 is a potent and selective PYK2 inhibitor, with an IC50 of 637 nM. PF-4618433 Chemical Structure
  85. GC15380 PF-562271 ATP-competitive FAK inhibitor, reversible PF-562271 Chemical Structure
  86. GC10810 PF-562271 HCl PF-562271 (VS-6062) hydrochloride is a potent, ATP-competitive and reversible FAK and Pyk2 kinase inhibitor with IC50s of 1.5 nM and 13 nM, respectively. PF-562271 HCl Chemical Structure
  87. GC11107 PF-573228 ATP-competitive FAK inhibitor PF-573228 Chemical Structure
  88. GC44613 PF-6274484 PF-6274484 is an inhibitor of the EGF receptor (EGFR; IC50s = 0.18 and 0.14 nM for wild-type EGFR and inhibitor-resistant EGFRL858R/T790M, respectively). PF-6274484 Chemical Structure
  89. GC65009 PF-6683324 PF-6683324 (Trk-IN-4) is a potent pan-Trk inhibitor in cell-based assays withIC50s of 1.9 nM, 2.6 nM and 1.1 nM for TrkA, TrkB and TrkC, respectively. PF-6683324 Chemical Structure
  90. GC19287 PF06650833 PF06650833 (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. PF06650833 Chemical Structure
  91. GC36888 PFE-360 PFE-360 (PF-06685360) is a potent, selective, brain penetrated and orally active leucine-rich repeat kinase 2 (LRRK2) inhibitor with a mean IC50 of 2.3 nM in vivo. PFE-360 Chemical Structure
  92. GC11733 PHA-665752 C-Met inhibitor,potent and ATP-competitive PHA-665752 Chemical Structure
  93. GN10503 Piceatannol

    Piceatannol (3,3′,4,5′-trans-trihydroxystilbene) is a naturally occurring hydroxylated analogue of resveratrol. 

     Piceatannol Chemical Structure
  94. GC50083 PKI 166 hydrochloride Potent EGFR-kinase inhibitor PKI 166 hydrochloride Chemical Structure
  95. GC40915 PKI-166 An inhibitor of EGFR PKI-166 Chemical Structure
  96. GC17925 PKR Inhibitor PKR Inhibitor (Compound C16) is a specific double-stranded RNA-dependent protein kinase (PKR) inhibitor. PKR Inhibitor Chemical Structure
  97. GC36940 PLX5622 A CSF1R inhibitor PLX5622 Chemical Structure
  98. GC38836 PLX5622 hemifumarate PLX5622 hemifumarate is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 ?M; Ki=5.9 nM). PLX5622 hemifumarate Chemical Structure
  99. GC15075 PLX647 dual inhibitor of FMS and KIT kinases PLX647 Chemical Structure
  100. GC15164 PND-1186 A potent FAK inhibitor PND-1186 Chemical Structure
  101. GC62111 PND-1186 hydrochloride PND-1186 hydrochloride (VS-4718 hydrochloride) is a potent, highly-specific and reversible inhibitor of FAK with an IC50 of 1.5 nM. PND-1186 hydrochloride selectively promotes tumor cell apoptosis. PND-1186 hydrochloride Chemical Structure

Items 701 to 800 of 1115 total

per page
  2. 6
  3. 7
  4. 8
  5. 9
  6. 10

Set Descending Direction